margetuximab
Selected indexed studies
- Margetuximab. (, 2006) [PMID:33355736]
- Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. (J Clin Oncol, 2023) [PMID:36332179]
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. (JAMA Oncol, 2021) [PMID:33480963]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Margetuximab. (2006) pubmed
- Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. (2023) pubmed
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. (2021) pubmed
- Margetuximab: Short Chapter. (2012) pubmed
- Margetuximab: First Approval. (2021) pubmed
- Margetuximab in HER2-positive metastatic breast cancer. (2023) pubmed
- Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer. (2022) pubmed
- Margetuximab for the treatment of HER2-positive metastatic breast cancer. (2021) pubmed
- Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. (2022) pubmed
- Margetuximab-cmkb. (2021) pubmed